Outcome of Board Meeting held on 21st May 2026

Profit growth above 25%Revenue growth above 20%Results View source PDF Explain this filing

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹665.00

prior close

₹656.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.1%+1.4% vs market

Specialty Chemicals peers, median of 93sector+0.1%+1.4% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.7

10m

-1.3

15m

-1.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.1+1.4+0.1+1.4

Next day

+4.7+1.7+3.0+0.9+3.8

+4.7+2.4+2.3+1.5+3.2

+1.5+2.4-0.9+1.3+0.2

+11.6+1.7+9.9+0.2+11.4

+16.8+0.6+16.2-0.9+17.7

+15.2+1.9+13.3-0.1+15.3

15d

+23.2+4.9+18.3+2.0+21.2

+24.7+8.9+15.7+4.7+19.9

+27.1+7.5+19.6+2.8+24.3

+68.9+13.6+55.3+5.5+63.4

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 93Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudeep Pharma's Board approved audited FY26 consolidated results showing strong performance with revenue from operations growing 28% to Rs. 64,225.80 lakhs from Rs. 50,199.92 lakhs in FY25. Profit after tax rose 25.6% to Rs. 17,428.47 lakhs, with EPS improving from Rs. 12.79 to Rs. 15.50. The Board recommended a final dividend of Rs. 1.50 per share (150% on Rs. 1 face value). The company completed its IPO in November 2025 raising Rs. 8,833.59 lakhs net proceeds, and acquired Nutrition Supplier & Services (Ireland) Limited as a step-down subsidiary in May 2025. Auditors BSR and Co issued an unmodified (clean) opinion on both standalone and consolidated results.

Likely market impact

Strong financial growth with 25%+ PAT growth signals solid operational performance. The company operates in two segments (Pharmaceutical/Food/Nutrition and Speciality Ingredients) both contributing to revenue. The clean audit opinion and dividend recommendation are positive signals for shareholders.